标题: About Agenix products Pipeline [打印本页] 作者: garyfu 时间: 2011-9-27 21:09 标题: About Agenix products Pipeline
本帖最后由 风雨不动 于 2012-4-14 14:48 编辑
Agenix has the ‘in principal’ rights to a number of product candidates, including the ‘in principal’ rights to develop and commercialise a secondary anti-hepatitis B drug, an anti-HIV drug, an anti colon cancer drug, and an anti liver cancer drug.
In September 2010, Agenix entered into an exclusive agreement with the Institute of Medicinal Biotechnology (IMB) of the Chinese Academy of Medical Sciences in Beijing to purchase, develop and commercialise a patented, novel targeted prodrug analog of an existing compound (Agenix product candidate AGX-1009). IMB is the major state institution in China for the discovery and development of anti-infectious drugs. AGX-1009 is one of the drug candidates supported by the Chinese Government’s State Special Funds for Important Newly-Developed Drugs.
Preliminary pharmacodynamics, pharmacokinetics and toxicity studies, performed by IMB, show that AGX-1009 has strong inhibition against HIV-1 and Hepatitis B (HBV) and also features a low toxicity profile and high oral bio-availability. Agenix will develop the drug for treatment of patients in China with chronic HBV. The patent for the compound does not expire until 2026.
[p=16, null, left]Agenix and IMB will collaborate to complete the regulatory requirements for the new drug and to obtain the production licence for it. Agenix will have responsibility for commercialising AGX-1009 in China.
[p=16, null, left]AGX-1009 is an anti-Hepatitis B drug that belongs to a new class of drugs called Nucleotide Analogue Reverse Transcriptase Inhibitors (NtRTI). The closest competitor of AGX-1009 is expected to be GSK/Gilead’s Tenofovir DF which obtained US Food and Drug Administration approval for HBV treatment in 2008 and could be approved by China’s State Food and Drug Administration by 2014. The body converts AGX-1009 into an active compound that works by interfering with the function of an enzyme (HBV DNA polymerase) that is essential for the replication of HBV.
AGX-1009 is a next generation prodrug that preliminary testing indicates will be an effective, once daily treatment for chronic HBV patients, including those in which the virus has developed resistance to current drugs.